Q-omics provides the consensus-scored TMEM41A profile across patient tissues and cancer cell-line models. TMEM41A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, TMEM41A is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, TMEM41A RNA expression shows 20,025 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, COAD, and ACC as cancer lineages where TMEM41A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM41A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM41A survival associations across molecular data types. TMEM41A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM41A RNA expression–survival associations across cancer types. High TMEM41A expression shows unfavorable associations in PAAD, UCEC, BRCA, LIHC and LUAD, but favorable associations in THCA. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for TMEM41A RNA expression.
This table summarizes TMEM41A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM41A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM41A shows higher tumor expression in COAD, HNSC, KIRP, THCA, BLCA and STAD. The COAD box plot shows higher TMEM41A RNA expression in tumor versus normal tissue (log2 FC = +1.081, t-test p < 0.001).
This table shows molecular features associated with TMEM41A in patient tissues and cancer cell lines. In patient samples, TMEM41A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM41A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
